Growth & profitability
- Revenue has declined 38.6% per year over the past 5 years.
- Operating margin has contracted, at -6056.4% in the latest year.
IMA Financials ImageneBio, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $800000 | -$45M | 0.0% | -6056.4% | — | — | $95M |
| 2024 | $4M | -$37M | 0.0% | -1057.1% | — | — | $12M |
| 2023 | $9M | -$68M | 0.0% | -823.3% | -$80M | — | $120M |
| 2022 | $16M | -$69M | 0.0% | -454.0% | -$76M | — | $60M |
| 2021 | $31M | -$34M | 0.0% | -110.2% | -$62M | — | $232M |
| 2020 | $9M | -$44M | 0.0% | -484.2% | -$39M | — | $162M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$11M | — | — | — | — | $76M |
| Dec '25 | $0 | -$7M | — | — | — | — | $95M |
| Sep '25 | — | -$25M | — | — | — | — | $103M |
| Jun '25 | — | -$8M | — | — | — | — | $58M |
| Mar '25 | $800000 | -$6M | 0.0% | -749.4% | — | — | $37M |
| Dec '24 | $0 | -$5M | — | — | — | — | $12M |
| Sep '24 | $4M | -$3M | 0.0% | -58.2% | — | — | $45M |
| Jun '24 | — | -$6M | — | — | — | — | $44M |
| Mar '24 | — | -$16M | — | — | — | — | $53M |
| Dec '23 | $659000 | -$19M | 0.0% | -3324.4% | -$22M | — | $120M |
| Sep '23 | $1M | -$17M | 0.0% | -1645.8% | -$20M | — | $121M |
| Jun '23 | $2M | -$17M | 0.0% | -922.7% | -$18M | — | $71M |
| Mar '23 | $5M | -$14M | 0.0% | -292.0% | -$20M | — | $29M |
| Dec '22 | $5M | -$14M | 0.0% | -277.3% | -$18M | — | $60M |
| Sep '22 | $6M | -$17M | 0.0% | -279.2% | -$18M | — | $67M |
| Jun '22 | $382000 | -$20M | 0.0% | -5484.6% | -$19M | — | $48M |
| Mar '22 | $3M | -$17M | 0.0% | -501.2% | -$20M | — | $47M |
| Dec '21 | $20M | $3M | 0.0% | 13.8% | -$14M | — | $232M |
| Sep '21 | $4M | -$15M | 0.0% | -387.7% | -$18M | — | $246M |
| Jun '21 | $4M | -$13M | 0.0% | -357.5% | -$16M | — | $264M |
Valuation over time
How the market has priced IMA against its own fundamentals since 2025-07 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 57.7× (Jul '25) to 84.2× (Jun '26).
P/S
Frequently asked questions
Is IMA growing its revenue and profit?
Over the past 5 years, ImageneBio, Inc.'s revenue has declined 38.6% per year. These are computed facts, not advice.
How much debt does IMA have?
As of FY2025, ImageneBio, Inc. reported — of total debt against $95M of cash.
What is IMA's profit margin?
In FY2025, gross margin was —, operating margin -6056.4%, and net margin -5668.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.